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Abstract
Background: Weight gain during chemotherapy in women with breast cancer is commonly reported.
However, there are important differences between studies that examined weight change during chemotherapy; e.g.
type of chemotherapy, menopausal status, time between body weight measurements and sample size. The
purpose of this meta-analysis was to quantify changes in body weight during chemotherapy for women with
breast cancer, taking these differences into account.
Methods: We identified relevant studies using PubMed, Scopus and Embase databases. The search was limited to
human studies published in English up to and including December 2015. Only studies among women with early
stage breast cancer treated with chemotherapy, with reported body weight before and after chemotherapy and
type of chemotherapy were included. Random-effect models were used, and heterogeneity between studies was
explored through stratified analyses and meta-regression. Sensitivity analyses were done to explore whether a
specific study markedly affected the results.
Results: In total 25 papers were found, including data from 2620 women. Overall, body weight increased during
chemotherapy: 2.7 kg (95% CI 2.0, 7.5) with a high degree of heterogeneity (I2 = 94.2%). Stratified analyses showed
weight gain in all strata, but did not substantially reduce heterogeneity. Univariate meta-regression showed less weight
gain in prospective studies compared to chart review studies (−2.0, 95% CI: -3.1, −0.8). Studies including
cyclophosphamide, methotrexate and 5-fluorouracil (CMF) regimes showed a greater weight gain compared to those
that did not (2.2, 95% CI: 1.1, 3.3); and papers published until the year 2000 showed a greater weight gain compared to
those published after 2000 (1.9, 95% CI:-0.8, 3.1). In the multivariate models only studies including CMF regimes and
studies published until 2000 were associated with significant weight gain of respectively 1.3 and 1.4 kg.
Conclusion: Despite the high heterogeneity, this meta-analysis shows significant weight gain during chemotherapy for
women with breast cancer. Weight gain was more pronounced in papers published until 2000 and women receiving
CMF as chemotherapy regime. Although weight gain after chemotherapy has decreased over the course of time, weight
gain is still substantial and deserves clinical attention.
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Background
Treatment for early stage breast cancer mostly consists of
a combination of surgery, radiotherapy, chemotherapy
and hormonal therapy. Chemotherapy can cause various
side effects, such as nausea, vomiting, hair loss, fatigue,
mucositis, cytopenia, ovarian failure and cardiac toxicity.
In addition, numerous studies have described weight gain
in women with breast cancer during chemotherapy [1–8].
Several reviews reported body weight gain during
chemotherapy for breast cancer patients [9–15]. Weight
gain during chemotherapy was first reported in 1978 by
Dixon et al. [16]. Mid-1990s reviews of the literature
suggest that significant weight gain occurred in 50–96%
of the breast cancer patients who received chemother-
apy. Weight gain was reported to vary from 2.5 to
6.2 kg, while gains of more than 10 kg were not unusual
[13, 14, 17]. More recent studies report a lower preva-
lence of weight gain (35–85%), with weight gain varying
between 1.4 to 5.0 kg [6–8, 18–20].
Body weight gain during chemotherapy treatment for
breast cancer is undesirable, since it has negative influ-
ences on quality of life and health. Weight gain during
treatment is associated with an negative affect on quality
of life and self-esteem. In addition, several studies
reported an increased risk of disease recurrence and
poorer prognosis, however, these results are inconsistent
[10, 15, 21–25]. A recent meta-analysis concluded that a
weight gain of 10% or more after diagnosis of breast
cancer is associated with higher all-cause mortality,
mainly attributable to 1 study [26].
There are important differences between studies that
examined weight change during chemotherapy in breast
cancer patients, which may partly explain the large vari-
ation in body weight changes observed between studies.
First, the amount and type of chemotherapy changed over
time, from cyclophosphamide, methotrexate and 5-
fluorouracil (CMF) in the 1970s and 1980s, to anthracy-
clines in the 1990s, to more taxane-based regimens
nowadays [27–29]. Second, characteristics of included pa-
tients differed between studies. Some studies investigated
only premenopausal women, while other studies included
both, pre- and postmenopausal women. A third important
difference is the time between the body weight measure-
ments. Some studies followed patients only during chemo-
therapy with body weight measured before and shortly after
chemotherapy. Other studies followed patients for a year or
even longer with varying moments of weight measurements
during follow-up. Fourth, the sample size varied substan-
tially between studies, ranging from less than 10 till more
than 200 participants. A fifth important difference is the
study design: some studies retrieved body weight as re-
ported in the medical records, while other studies had a
prospective design with standardized measurements of
body weight before, during and after chemotherapy.
Reviews regarding body weight gain during chemo-
therapy for breast cancer patients were narrative reviews
and did not provide summary estimates for weight
change so far. Therefore, the purpose of this meta-
analysis was to quantify changes in body weight during
chemotherapy for women with early stage breast cancer,
and to assess which factors contributed to the hetero-
geneity between studies.
Methods
Literature search
A comprehensive search of literature was conducted
using PubMed, Scopus and Embase databases. Search
term included: “body weight change”, “body weight”,
“breast cancer”, “breast neoplasm”, “breast carcinoma”,
“breast tumor”, “breast tumour”, “breast adenoma”,
“mamma,” “chemotherapy”, “chemo” and “cytostatic”
(see Additional file 1 for more details). The search was
limited to human studies, published in English up to and
including December 2015. In addition, references listed
in papers were screened for additional papers, resulting
in the inclusion of one additional paper.
Paper selection
Papers were included if they met the following criteria:
early stage breast cancer patients treated with chemo-
therapy, type of chemotherapy reported, at least two
measurements of body weight: one before and one after
chemotherapy treatment. Both observational and inter-
vention studies were included. Intervention studies were
included if they included a control group receiving usual
care; only the information of this usual care group was
included in the meta-analysis.
One database was created and duplicate references
were deleted. First, titles were screened on eligibility by
two researchers (MB and RW). Secondly, abstracts were
screened. If an abstract did not contain sufficient infor-
mation to assess eligibility, the full-text was reviewed to
assess eligibility. Communication letters, abstracts and
poster of conferences were excluded.
Data extraction
From each relevant paper, information on first author, year
of publication, country, study design, sample size,
characteristics of study population (baseline age, baseline
height, baseline menopausal status), breast cancer stage,
type of chemotherapy, duration of chemotherapy, follow-
up period between measurements of weight, adjuvant/neo
adjuvant chemotherapy, time points of weight assessment
in relation to start and stop dates of chemotherapy, and
weight or weight change (kg) with standard deviation
(SD), 95% confidence interval or range were extracted and
stored in a database.
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Quality assessment
To assess whether studies of lesser quality could have
influenced the results, two researchers (MB and RW)
independently assessed the quality of the included stud-
ies using an adapted version of the Newcastle-Ottawa
Scale for assessing the quality of nonrandomised studies
[30]. Studies could get a maximum of 6 points, in four
quality areas: 1) representativeness of the sample (infor-
mation about number of people eligible and included);
2) loss to follow-up of participants (information about
number lost to follow-up); 3) information about expos-
ure (type of chemotherapy regimens); 4) assessment of
the outcome (information how body weight was
assessed). The rating system scores studies from 0 (low
quality) to 6 points (high quality). A total score of 3 or
less points was considered low quality, whereas a score
of 4 or more points was considered high quality.
Statistical analysis
When no mean body weight change or SE was reported
these were calculated if possible for each paper. When
data on mean baseline weight and height were available
we calculated the baseline mean BMI for the total
group of participants using the formula: BMI = weight
(kg) /height2 (m). If weight or weight change was re-
ported for different types of chemotherapy or meno-
pausal status separately, these results were included
instead of the overall mean weight change. Random-
effect models were used to calculate the mean and
95% confidence interval of the weight change during
chemotherapy for breast cancer. Statistical heterogen-
eity between studies was assessed by the I2 statistic.
I2 of 25%, 50% or 75% were interpreted as indicating
low, moderate and high heterogeneity, respectively
[31]. To investigate potential sources of heterogeneity,
we conducted stratified analyses. These included the
factors: type of chemotherapy (CMF included vs no
CMF included), sample size (n = <100 vs n= > 100),
menopausal status (premenopausal, postmenopausal,
both), baseline mean BMI (20.0–24.9 vs 25.0–29.9),
study design (prospective vs chart review), second
measurement of body weight (the end of chemother-
apy /6 months after baseline’ group and vs ‘6 months
after chemotherapy/12 months after baseline’ group),
year of publication (before and including 2000 vs
after 2000), country (US, Canada, Western Europe,
Australia, Turkey, Korean) and study quality (low quality
vs high quality). Of all factors included in the stratified
analysis with data available of all estimates we conducted
meta-regression analyses. We included the factors that
were statistically significant in the univariate stratified ana-
lyses in a multivariate regression analysis. Regression coef-
ficients, 95% confidence intervals and p values were
reported. Sensitivity analyses were conducted by excluding
one study at a time to explore whether one study mark-
edly affected the results or highly contributed to the het-
erogeneity. A second sensitivity analysis was conducted by
excluding the only intervention study included. Finally,
sensitivity analyses were done excluding studies included
<50 participants, and excluding studies included >200 par-
ticipants to explore whether the smallest or largest studies
markedly affect the results. Statistical analyses were con-
ducted using STATA version 11 (StataCorp, College Sta-
tion, TX). A p-value <0.05 was considered statistically
significant.
Results
The results of the literature search and study selection
are summarized in Fig. 1. In total the database searches
yielded 2445 references. After duplicates were deleted
2022 titles and 138 abstracts were screened for eligibility.
A total of 52 full texts were screened, of which 27 papers
were excluded, resulting in 25 eligible papers. Papers
were excluded for the following reasons: full-text could
not be obtained (n = 2); articles did not report a weight
change (n = 4); articles included a variety of cancer types
and did not report results for breast cancer separately
(n = 3); articles did not report weight changes during
chemotherapy (n = 3); weight change was not reported
in kg, but only as percentage change (n = 4); type of
chemotherapy was not reported (n = 4); chemotherapy
was combined with other treatment e.g. radiotherapy
(n = 4); only an intervention group (n = 2). One paper
was excluded because a more recent paper about the
same study was published. In total, 34 weight change
estimates from 25 papers were included in this meta-
analysis. Six papers reported results for weight gain in
subgroups receiving different kind of chemotherapy
treatments.
Characteristics of the participants and study designs
Characteristics of the studies included in this meta-
analysis are shown in Table 1. The 25 papers were
published between 1985 and the end of 2015. Thirteen
weight change estimates were published up to and in-
cluding 2000 [17, 32–38], and 21 after 2000 [1, 6–8, 12,
18–20, 39–47]. In total, 20 weight change estimates in-
cluded patients treated with CMF. Sixteen weight esti-
mates retrieved body weight from medical chart review.
Eighteen had a prospective design of which one body
weight estimate was an intervention study. Sample size
of the body weight estimates varied from 8 to 483 partic-
ipants. All papers used body weight before start of
chemotherapy as baseline measure. For the second time
point of measurement we created two groups: 1) ‘the
end of chemotherapy /6 months after baseline’ group
and 2) ‘the 6 months after chemotherapy/12 months
after baseline’ group. The first group contained studies
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for which the second measurement was either directly
after chemotherapy or 6 months after diagnosis, the sec-
ond group all studies for which the second measurement
was 6 months after chemotherapy or 12 months after
diagnosis.
Overall, data from 2620 women were included in this
meta-analysis. The mean age of the study samples
ranged from 39 to 56 years. Most papers included a
combination of pre- and postmenopausal women. Seven
papers included only premenopausal women. Two
papers showed results separately for pre- and postmeno-
pausal women. Table 2 gives an overview of the quality
assessment of the studies included in this meta-analysis.
Eight papers scored a total of three or less points for
study quality and were assessed as low quality studies.
Overall estimate
Mean weight change reported in the papers ranged from
−0.8 to 7.7 kg. A gain in body weight was reported in 31
of the 34 estimates, Fig. 2. The pooled mean weight
change was 2.7 kg (95% CI: 2.0–3.3) with a heterogeneity
of 94.2%. To further explore this high heterogeneity,
stratified analyses were conducted.
Stratified and sensitivity analyses
Body weight change estimates were stratified by type of
chemotherapy, sample size, menopausal status, baseline
BMI, study design, time between body weight measure-
ments, year of publication, country, and study quality
see Table 3. Overall, weight gain was observed in all
strata. Stratified analyses did not substantially reduce
heterogeneity. The high heterogeneity remained for most
subgroups except for the body weight change estimates
in studies with a normal mean BMI at baseline
(I2 = 45.1%) who had a low heterogeneity and estimates
not including CMF (I2 = 74.7%), including studies with a
mean BMI >25 at baseline (I2 = 73.2%) and for prospect-
ive studies (I2 = 69.5%), which all showed a moderate
heterogeneity.
Sensitivity analyses excluding one study at a time did
not markedly influence the overall result of weight
change (range 2.4–2.8 kg) nor did importantly affect the
amount of heterogeneity (range I2 89.2–94.6%), neither
did excluding the smallest or largest studies. In
addition, excluding the intervention study did also
not markedly influence the overall result of weight
change 2.7 kg (95% CI: 2.0–3.4) [42].
Fig. 1 Paper screening and data extraction progress
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Of the 21 body weight change estimates from studies
published after 2000, 10 estimates included women
treated with CMF. The main weight change in the body
weight change estimates from studies after 2000 includ-
ing women treated with CMF was 2.8 kg (95% CI: 2.0,
3.5) compared to 1.0 kg (95% CI: 0.5, 1.5) in those that
did not include women treated with CMF.
Meta-regression analysis
Results of the meta-regression analyses are shown in Table
4. Results of the univariate model showed that weight gain
was significantly different for body weight estimates from
studies including CMF vs estimates from studies not in-
cluding CMF, for studies using chart review vs prospective
studies, and for studies published before 2000 vs studies
published after 2000. In the multivariate model, we stud-
ied the combined effect of type of chemotherapy, study
design and year of publication. In this model type of
chemotherapy and year of publication remained signifi-
cantly associated with body weight change, although the
body weight change estimates were attenuated. Study de-
sign was no longer statistically significantly associated with
body weight change in the multivariate model. The re-
sidual I2 for the multivariable regression model was 84.8%,
indicating that these factors explained only a small part of
the heterogeneity.
Discussion
The present work is the first meta-analysis that quanti-
fied changes in body weight during chemotherapy in
Table 2 Summary of the quality assessment of included studies using an adapted version of the Newcastle-Ottawa scale for
assessing the quality of nonrandomised studies
First author, year of
publication
Representativeness of
sample (2 points)
Loss to follow-up of
participants (1 point)
Information about
exposure (1 point)
Measurement of
outcome (2 points)
Total score
Foltz, 1985 [32] 2 1 1 1 5/6
Heasman, 1985 [33] 2 1 1 1 5/6
Huntington, 1985 [34] 1 0 1 1 3/6
Goodwin, 1988 [35] 2 1 1 1 5/6
Demark-Wahnefried, 1997 [13] 1 1 0 1 3/6
Aslani, 1999 [36] 1 1 1 1 4/6
Goodwin, 1999 [37] 1 1 0 2 4/6
Kutynec, 1999 [38] 2 1 1 1 5/6
Demark-Wahnefried, 2001 [12] 2 1 0 2 5/6
McInnes, 2001 [1] 1 1 0 1 3/6
Del Rio, 2002 [39] 1 1 1 0 3/6
Lankester, 2002 [40] 1 1 0 1 3/6
Freedman, 2004 [7] 1 1 0 2 4/6
Harvie, 2004 [18] 1 1 0 2 4/6
Ingram, 2004 [6] 2 1 1 2 6/6
Kumar, 2004 [41] 2 1 0 1 4/6
Campbell, 2007 [19] 1 1 0 2 4/6
Courneya, 2007 [27] 2 1 0 1 4/6
Makari-Judson, 2007 [20] 2 1 0 1 4/6
Heideman, 2009 [8] 2 1 0 1 4/6
Biglia, 2010 1 1 0 0 2/6
Tredan, 2010 [44] 1 1 0 1 3/6
Basaran, 2011 [45] 1 0 0 1 2/6
Jeon, 2014 [46] 1 1 1 1 4/6
Winkels, 2014 [47] 2 1 1 1 5/6
(1) Representativeness of sample (2 points: extensive information on number of people eligible and included, 1 point: extensive information about recruitment,
but not about number of people eligible and included, 0 points: only brief information about recruitment. (2) Loss to follow-up of participants (1 point: information
about number lost to follow-up; 0 points: no information about number lost to follow-up). (3) information about exposure (1 point: results are given separate for
different chemotherapy regimens, 0 points: results are not separated out for chemotherapy regimens). (4) assessment of the outcome (2 points: measurement
protocol for body weight, 1 point: body weight information for chart review or measurement without protocol, 0 points: no information on how body weight was
assessed). The rating system scores studies from 0 (low quality) to 6 points (high quality)
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women with early stage breast cancer. Based on 25
papers, a mean weight gain of 2.7 kg (95% CI: 2.0–3.3)
was observed with a heterogeneity of 94.2%. Stratified
analysis showed weight gain in all strata, but the strata
could only marginally explain the heterogeneity. Ad-
justed weight gain estimates based on body weight esti-
mates from studies including patients treated with CMF
and papers published before 2000 were larger compared
to estimates from studies in which CMF was not
included and papers published after 2000. Despite the
high heterogeneity which could only partly be explained,
the results of this meta-analysis suggest constant and
significant weight gain during chemotherapy for women
with early stage breast cancer.
Treatment for breast cancer has changed over time.
Before the 1990s, only CMF was used as chemotherapy
regime, while during the 90s the use of anthracyclines
gradually increased. In studies after 2004, taxane-based
chemotherapy was introduced as a treatment for early
stage breast cancer. In the current meta-analysis, CMF
emerged as a chemotherapy associated with weight gain,
which use has importantly decreased over time. How-
ever, our meta-analyses also showed that in studies pub-
lished after the year 2000 the mean weight gain was still
considerable 1.3 kg. Stratified by type of chemotherapy,
the mean weight change from studies published after
2000 and including women treated with CMF was 2.8 kg
compared to 1.0 kg in those that did not include women
treated with CMF. These data suggest that the abandon-
ing of CMF as the chemotherapeutic regimen of choice
could be an important reason for observing less weight
gain in more recent studies. Independently of CMF, time
of publication was associated with weight gain. A pos-
sible reason why studies after 2000 observed less weight
gain relative to earlier studies could be the incremental
use of taxanes in more recent years. However, as the
studies included in this meta-analysis did not all provide
detailed information on type of chemotherapy, we can
only speculate on that.
Another possible explanation for differences in
weight gain between older and more recent studies
could be age and BMI at baseline. However, we did
I-V Overall  (I-squared = 94.2%, p = 0.000)
Heasman, 1985
Tredan, 2010
Kunmar, 2004
Freedman, 2004
Biglia, 2010
McInnes, 2001
Heideman, 2009
Winkels, 2014
D+L Overall
Campbell, 2007
Study
Ingram,2004
Huntington, 1985
Tredan, 2010
Harvie, 2004
ID
Ingram,2004
Aslani, 1999
Heasman, 1985
Demark-Wahnefried, 1997
Jeon, 2014
Goodwin, 1999
Heasman, 1985
Del Rio, 2002
Basaran, 2011
Lankester, 2002
Goodwin, 1988
Courneya, 2007
Ingram,2004
Huntington, 1985
Huntington, 1985
Kutynec, 1999
Demark-Wahnefried, 2001
Makari-Judson, 2007
Goodwin, 1988
Heideman, 2009
Foltz, 1985
3.17 (3.04, 3.30)
2.72 (2.07, 3.37)
1.20 (0.59, 1.81)
0.40 (-1.81, 2.61)
-0.83 (-2.42, 0.76)
2.07 (1.19, 2.95)
3.40 (2.75, 4.05)
2.20 (-1.86, 6.26)
1.20 (0.71, 1.69)
2.65 (1.99, 3.32)
1.98 (-7.94, 11.90)
1.00 (0.33, 1.67)
2.63 (1.22, 4.04)
0.20 (-0.45, 0.85)
3.30 (1.30, 5.30)
ES (95% CI)
5.00 (1.47, 8.53)
2.35 (1.13, 3.57)
6.20 (5.42, 6.98)
0.00 (-6.82, 6.82)
3.64 (-3.61, 10.89)
2.50 (1.79, 3.21)
3.65 (3.02, 4.28)
2.80 (1.70, 3.90)
1.70 (-0.14, 3.54)
3.68 (2.90, 4.46)
5.55 (4.33, 6.77)
1.20 (-2.15, 4.55)
1.50 (-0.01, 3.01)
4.76 (4.52, 5.00)
7.67 (5.93, 9.41)
0.00 (-5.59, 5.59)
2.20 (1.47, 2.93)
2.60 (1.48, 3.72)
2.51 (2.04, 2.98)
2.60 (-0.71, 5.91)
2.99 (-2.60, 8.58)
100.00
4.29
4.86
0.37
0.71
2.31
4.29
0.11
7.47
0.02
Weight
4.04
0.90
4.29
0.45
(I-V)
0.14
1.22
2.92
0.04
0.03
3.60
4.56
1.49
0.53
2.92
1.22
0.16
0.79
32.44
0.59
0.06
3.41
1.44
8.11
0.16
0.06
%
0-10 h
Fig. 2 Weight change during chemotherapy for early stage breast cancer. Mean weight changes in individual estimates are depicted as squares
with 95% confidence intervals (CI). Pooled estimates with 95% CI are depicted as open diamonds
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not see a difference in baseline age and mean BMI
comparing older and more recent studies. Yet, since
most studies included in this meta-analysis did not
provide detailed information and stratified results on
baseline BMI, we could not explore this in detail.
Weight gain appeared to be less in prospective studies
than in chart review studies in our meta-analysis. A pos-
sible explanation for this finding is, that in prospective
studies, data usually were collected as part of a cohort
or other observational study. These studies could
Table 3 stratified pooled mean weight change and 95% confidence interval in women during chemotherapy treatment for early
stage breast cancer
No of estimates Pooled weight change kg 95% CIa I2b
Overall
All 34 2.7 2.0, 7.5 94.2
Type Chemotherapy
CMF included 20 3.5 2.7, 4.3 93.7
No CMF 14 1.4 0.7, 2.0 74.7
Menopausal status
Premenopausal 9 2.6 1.5, 3.6 86.9
Postmenopausal 2 1.3 −1.1, 3.7 89.4
Perimenopausal 1 4.8 4.5, 5.0
Combination 22 2.7 2.0, 3.4 88.3
Baseline mean BMI
20.0–24.9 6 0.5 −0.4; 1.3 45.1
25.0–29.9 15 2.4 1.8; 3.6 73.2
Unknown 13 3.5 2.6; 4.5 95.4
Follow-up 93.8
end of chemotherapy / 6 months after baseline 26 2.7 2.0; 3.5 90.9
6 months after chemotherapy / 12 months after baseline 8 2.4 1.3; 3.4
Type of study
Chart review 16 3.6 2.8, 4.4 94.8
Prospective 18 1.6 1.1, 2.2 69.5
Publication year
Before and including 2000 13 3.8 2.9, 4.7 93.3
After 2000 21 1.9 1.3, 2.5 81.6
Sample Size
≤ 100 23 3.0 2.2, 3.9 92.7
> 100 11 2.1 1.3, 2.8 90.1
Country
United States 10 2.8 1.6; 4.1 93.4
Canada 12 3.1 2.1; 4.1 91.8
Western Europe 9 2.0 1.1; 2.8 86.2
Australia 1 2.4 1.1;3.6
Turkey 1 1.7 −0.1; 3.5
Korea 1 3.6 −3.6; 10.9
Study quality
Low quality 11 2.9 1.6; 4.1 96.7
High quality 23 2.5 1.8; 3.2 88.8
aConfidence interval
b12 = the percentage heterogeneity due to between-study variation
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potentially include a selected (e.g. high SES) population,
which make them less generalizable to the general popu-
lation. Chart review papers usually included all patients
treated with chemotherapy in a retrospective period of
time, but completeness of data was not clearly reported
in all studies. Thus both, chart reviews and prospective
studies may suffer from incomplete data and selection
issues, but as studies did not provide detailed informa-
tion on response rates and possible selection, we could
not explore this further in our meta-analysis. Moreover,
stratified results on study quality did not show any
differences between studies considered as low quality
compared to studies considered of high quality, neither
did stratifying on study quality reduce heterogeneity.
An earlier narrative review suggested that women with
a normal BMI at baseline were more likely to gain
weight compared to women who were overweight at
diagnosis [15], however other studies did not confirm
this [37, 44] Since only one study included in this meta-
analysis reported results for weight change stratified in
categories of baseline BMI, we could not study this in
great detail. Nevertheless, our analyses suggested a lower
Table 4 Results from multivariate meta-regression analysis on weight change in subgroups of early stage breast cancer patients
during chemotherapy
Unadjusted Adjustedd
RCa SEb 95% CIc P-value RC SE 95% CI P-value
Type chemotherapy
No CMF ref ref
CMF included 2.2 0.6 1.1, 3.3 <0.01 1.4 0.6 0.3, 2.6 0.02
Menopausal status
Premenopausal ref
Postmenopausal −1.3 1.4 −4.1, 1.5 0.36
Perimenopausal 2.2 1.8 −1.5, 5.8 0.23
Combination 0.1 0.8 −1.5, 1.6 0.91
Follow-up
end of chemotherapy / 6 months after baseline ref
6 months after chemotherapy / 12 months after baseline −0.1 0.1 −0.3; 0.2 0.64
Type of studie
Chart review ref ref
Prospective −2.0 0.6 −3.1, −0.8 <0.01 −0.7 0.6 −1.9, 0.5 0.24
Publication year
After 2000 ref ref
Before and including 2000 1.9 0.6 0.8, 3.1 <0.01 1.3 0.5 0.2, 2.3 0.02
Sample Size
≤ 100 ref
> 100 −1.0 0.7 −2.3, 0.4 0.15
Country
United States ref
Canada −0.2 0.9 −1.5; 2.0 0.79
Western Europe −0.8 0.9 −2.6; 1.0 0.39
Australia −0.5 1.9 −4.5; 3.5 0.80
Turkey −1.1 2.1 −5.4; 3.1 0.58
Korea 0.8 4.1 −7.7; 9.3 0.85
Quality assessment
Low Quality ref
High Quality −0.4 0.7 −1.8; 1.0 0.58
aRegression coefficient
bStandard error
cConfidence interval
dAdjusted for, type of chemotherapy, type of study and publication year
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weight gain in studies with a mean normal BMI at
baseline compared to studies with mean BMI > 25 at
baseline. These results should be interpreted carefully,
since they represents mean BMI for the total study,
which does not mean that all women in that study fall
within that BMI category. If the man BMI of a study
population is lower, other possible confounding factors
may also differ from studies in which mean BMI is
higher. However, as this is speculative, and data on other
confounding factors is limited, we could not study this
further. An important factor in the interpretation of our
results is that heterogeneity of our estimates remained
high despite elaborate analyses to explore possible
sources of heterogeneity, including stratification and
meta-regression. This high heterogeneity suggests that
other, less studied factors may importantly contribute to
weight gain during chemotherapy. A factor that could
contribute is ovarian failure which is especially relevant
for premenopausal women. This ovarian failure impacts
hormonal levels, which may possibly be related to
subsequent weight gain. Nevertheless, in the current
meta-analyses we did not observe differences in weight
gain between pre- and postmenopausal women, possibly
because only a small part of the studies stratified for
menopausal status [48]. Weight gain may also be
explained by common side-effects of chemotherapy such
as fatigue, potentially reducing habitual physical activity
[17, 49]. Recently, special programs are implemented in
breast cancer care in various countries stimulating
physical activity. These added interventions may explain
differences between older and more recent studies. Also,
chemotherapy may induce changes in taste and smell
possibly leading to changes in dietary eating patterns
which could influence body weight [50]. However, little
research has focused on these sensory effects. Further-
more, reductions in energy expenditure in rest have been
reported during and after chemotherapy which may lead
to an increase in body weight [15, 10]. As most studies
did not publish on these potential factors, we could not
explore whether they were possible sources of hetero-
geneity in our meta-analysis.
A limitation of our study is that we could not explore
duration of chemotherapy as a source of heterogeneity.
Chemotherapy duration has decreased nowadays. Litera-
ture suggest that duration of chemotherapy could be an
important factor to weight gain [15, 17, 10]. In this meta-
analyse it was not possible to explore this since most
studies did not report the duration of chemotherapy.
Another limitation is that we used the year that the
manuscript was published and not the years the partici-
pants were enrolled into the study: time between con-
ducting the study and publishing the results may vary
between studies. Although year of enrolment would have
been preferable, for 13 estimates this information was
available. A sensitivity analysis using only the 21
estimates that had this information available showed a
comparable trend of a decrease in weight gain for more
recent studies (data not shown).
Also we could only study changes in weight, but not
in fat or fat-free mass. Future studies should provide
more detailed information on body weight trajectories
and preferably body composition, as changes in fat and
lean mass may be more clinically relevant. In addition,
future studies should also report percentage of women
with a significant weight loss, gain or maintenance
rather than only mean weight change, so it is possible to
establish the clinical magnitude of changes in body
weight during chemotherapy.
A strength of this study is that it is, to the best of our
knowledge, the first meta-analysis conducted on weight
gain in breast cancer women during chemotherapy. A
comprehensive literature search was conducted includ-
ing an additional hand search. This makes the potential
of missing any published data in English unlikely.
Conclusions
In conclusion, our results indicate that women generally
gain weight during chemotherapy for early stage breast
cancer. This weight gain is more pronounced in women
treated with CMF and is greater in studies published be-
fore 2000. Although weight gain after chemotherapy has
decreased over the course of time, weight gain is still
substantial and deserves clinical attention.
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